Novo Nordisk starts trialing lower maintenance doses of oral Wegovy

Summary

Novo Nordisk has initiated a Phase 3 study evaluating lower maintenance doses of oral Wegovy in patients with obesity or overweight, combined with lifestyle modifications including reduced-calorie diet and increased physical activity.